Gottlieb: Staged Access To Coronavirus Vaccine Possible Through EUA
Former FDA Commissioner says agency could grant an EUA for a vaccine, but require it meet the standard for full approval, and then roll it out gradually with postmarket data collection.
You may also be interested in...
COVID Vaccine Postmarket Monitoring Will Depend On Which Adverse Events US FDA Wants To Watch
US FDA has the unenviable task of picking the most important adverse events to track once coronavirus vaccinations begin; CDC's list will need to be winnowed to 10-20 to make the surveillance feasible, and which AEs make the cut may be informed by the vaccine trials, as well as clinical experience with COVID infections.
US FDA Expects COVID-19 Vaccines To Meet ‘EUA Plus’ Standards, Marks Says
CBER director said that all the manufacturing data may not be available, but the safety and efficacy data needed for a BLA are expected before an emergency use authorization is granted.
COVID-19 Vaccine Sponsors’ Pledge To Wait For Phase III Helps US FDA
The move reduces the pressure on the companies to rush development, but also relieves burden on the FDA to approve a candidate too soon.